GOOSE Society of Texas has invested in a chemical sensor company from Austin. Pexels

A Houston-based investment group has announced funding for a startup out of Austin that has the potential to disrupt multiple industries with its chemical sensor device.

GOOSE Society of Texas, a group of investors that invest over $50 million into early stage startups, led the $2.6 million round for Lantha Inc. The startup plans to use the funds for finalizing its commercial products, strategic hires, and expand its intellectual property. The device Lantha has created can detect solid-state chemicals, which can be used in a myriad of industries from pharmaceuticals and oil and gas to water and defense.

Jeff Smisek, former United Airlines CEO and founder of investment firm Flight Partners Management LLC, was the GOOSE investor to lead the deal. According to a news release, he will join Lantha's board of directors.

"Lantha is a great example of the GOOSE Society's investment thesis — a company with proprietary and disruptive technology, low capital costs, large addressable markets, speedy product development and high margins which can benefit from the vast experience and contacts of the GOOSE Society's investors," Smisek says in the release. "We are proud to lead this financing and look forward to working closely with Lantha's management and world class scientists as they build a powerhouse in the field-based chemical analysis market."

Simon Humphrey, associate professor of chemistry at the University of Texas, invented the handheld device that is faster, cheaper, and easier to use than traditional tools. Humphrey serves as CTO for the company, and Robert Toker is the CEO and chairman of Lantha.

"We have world class scientists, who are the inventors of our technology, and a strong founding team, and we've attracted a great group of investors led by Jeff Smisek and the GOOSE Society in Houston as well as several prominent investors associated with the University of Texas at Austin," Toker says. "... Partnering with GOOSE has materially improved our chances of success."

The Lantha investment represents the first time GOOSE has funded technology coming out of UT.

"We are excited about expanding GOOSE's investment efforts to UT and look forward to future collaborations and deals," says Samantha Lewis, director at GOOSE. Several high-profile investors from the UT community invested in Lantha's Series A Preferred Stock alongside GOOSE investors.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

TMC launches new biotech partnership with Republic of Korea

international collaboration

Houston's Texas Medical Center has launched its new TMC Republic of Korea BioBridge.

The new partnership brings together the TMC with the Osong Medical Innovation Foundation, or KBIOHealth. The Biobridge aims to support the commercialization of Korean biotech and life science startups in the U.S., foster clinical research, and boost collaboration in the public, private and academic sectors.

Through the partnership, TMC will also develop a Global Innovators Launch Pad to foster U.S. market entry for international health care companies. Founders will be selected to participate in the 10-week program at the TMC Innovation Factory in Houston.

“Gene and cell therapies are driving biotech innovation, opening possibilities for treating diseases once thought untreatable," William McKeon, president and CEO of the Texas Medical Center, said in a news release. "Expanding biomanufacturing capacity is essential to delivering the next wave of these therapies, and partnerships with leading innovators will strengthen our efforts in Houston and internationally.”

McKeon officially signed the TMC Korea BioBridge Memorandum of Understanding with Myoung Su Lee, chairman of KBIOHealth, in South Korea in October.

"This collaboration marks a significant milestone for Korea’s biohealth ecosystem, creating a powerful bridge between Osong and Houston," Lee added in the release. "By combining KBIOHealth’s strength in research infrastructure and Korea’s biotech talent with TMC’s global network and accelerator platform, we aim to accelerate innovation and bring transformative solutions to patients worldwide.”

This is the seventh international strategic partnership for the TMC. It launched its first BioBridge with the Health Informatics Society of Australia in 2016. It launched its TMC Japan BioBridge, focused on advancing cancer treatments, last year. It also has BioBridge partnerships with the Netherlands, Ireland, Denmark and the United Kingdom.